Results 231 to 240 of about 41,938 (307)

Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience. [PDF]

Front Immunol
Marneni N, Lessans S, Dholaria B, Sengsayadeth S, Biltibo EA, Patel V, Bhaskar S, Jayani R, Mohan S, Kishtagari A, Morgan D, Oluwole OO, Savani BN, Kassim AA, Baljevic M.   +14 more
europepmc   +1 more source

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Relapse after chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T‐cells as standard second‐line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown because no real‐world data are currently ...
Pierre Sesques, Guillaume Manson, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Cristina Castilla‐Llorente, Gabriel Brisou, Pierre Bories, Catherine Thieblemont, Laurianne Drieu La Rochelle, Benoit Tessoulin, Axel André, Cedric Rossi, Jérôme Paillassa, Stephanie Guidez, Antoine Capes, Laura Herbreteau, Sylvain Choquet, Jacques‐Olivier Bay, Adrien Chauchet, Laure Lebras, Fabien Claves, Julie Abraham, Jean‐Valère Malfuson, Marie‐Thérèse Rubio, Justine Decroocq, Luc‐Matthieu Fornecker, Gandhi Damaj, Ludovic Fouillet, Magalie Joris, Michael Loschi, Olivier Hermine, Hadia Hafirassou, Emelie Van Zele, Vivien Dupont, Steven Le Gouill, Roch Houot, Vincent Camus   +37 more
wiley   +1 more source

Bispecific antibody for lung cancer: mechanisms and clinical insights. [PDF]

Front Immunol
Chen W, Zhou A, Zhou Y.
europepmc   +1 more source

Single-domain antibodies for brain targeting [PDF]

, 2014
Lalatsa, Katerina, Moreira Leite, Diana
core   +1 more source

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT Oligo‐secretory and non‐secretory MM present a clinical challenge due to the difficulties in initial diagnosis, response to treatment assessment, and relapse detection. They are excluded from most clinical trials, which typically require measurable disease.
Iuliana Vaxman, Itai Zamir, Inbar Cohen, Gil Fridberg, Tamir Shragai, Svetlana Trestman, Tomer Ziv Baran, Efrat Luttwak, Ronit Shmuel, Natan Melamed, Shai Levy, Irit Avivi, Pia Raanani, Angela Dispenzieri, Morie A. Gertz, Yael C. Cohen   +15 more
wiley   +1 more source

Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma. [PDF]

Haematologica
Siegel A, Reci S, Grossman L, Gleason C, Crary J, Song L, Park J, Verina D, Desai S, Kappes K, Stillman I, LaBaer J, Aleman A, Jagannath S, Parekh S.   +14 more
europepmc   +1 more source

Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus‐2

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Since its emergence in 2019, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) has caused a global pandemic driven by rapid mutation and high transmissibility. Current therapeutic strategies may not effectively address the continuously evolving mutant strains, underscoring the need for treatments with broad neutralizing activity ...
Da Sol Kim, Uijin Kim, Hye‐Min Woo, Hansaem Lee, Eun‐Seong Jo, Min Jeong Noh, So‐Young Lee, Byoung Kwon Park, Jeong‐Sun Yang, Kyung‐Chang Kim, Joo‐Yeon Lee, Dong‐Min Wang, Hyun‐Soo Cho, Hyun‐Joo Kim   +13 more
wiley   +1 more source

Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema. [PDF]

BMJ Open Ophthalmol
Wang Z, Sun J, Liu K, Tao L, Liu Q, Wu M, Lu S, Deng J, Li L, Qian L, Li X, Sun X.   +11 more
europepmc   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

MedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source